In vitro validation of 99mTc-HFA-FP delivered via pMDI-spacer.

Christina M Roller, Nicole C Schaefer, Guicheng Zhang, Sunalene G Devadason
{"title":"In vitro validation of 99mTc-HFA-FP delivered via pMDI-spacer.","authors":"Christina M Roller,&nbsp;Nicole C Schaefer,&nbsp;Guicheng Zhang,&nbsp;Sunalene G Devadason","doi":"10.1089/jam.2006.19.254","DOIUrl":null,"url":null,"abstract":"<p><p>The purpose of the study was to label Flixotide (fluticasone propionate [FP] with HFA propellant), with technetium-99m and validate that (99m)Tc acts as a suitable marker for FP when delivered via pMDI-spacer. Sodium pertechnetate was mixed with 5 mL of butanone. (99m)Tc was extracted into butanone and transferred into an empty canister. The (99m)Tc lined canister was heated, and the butanone evaporated to dryness. A supercooled commercial Flixotide canister was decrimped, and the contents transferred to the (99m)Tc lined canister and recrimped. The particle size distribution of FP and (99m)Tc from 10 radiolabeled canisters was measured using an Anderson cascade impactor calibrated to 28.3 L/min, and compared to commercial FP. The drug (FP) content of each particle size fraction was measured using ultraviolet spectrophotometry and the (99m)Tc level in each fraction was measured using an ionization chamber. The percentage of particles in the fine particle fraction (<;4.7 microm) and the percentage of (99m)Tc from commercial and radiolabeled canisters were compared. The mean (SD) % FP in the fine particle fraction, before and after label was 43.2 (1.8) % and 43.9 (2.6) %, respectively. The mean (SD) % (99m)Tc in the fine particle fraction was 42.1 (5.1) %. The mean %FP exiting spacer at (<4.7 microm) before labeling was not significantly different from the mean % FP exiting spacer at (<4.7 microm) after labeling (p > 0.05). The mean % (99m)Tc attached to particles at (<4.7 microm) after radiolabeling was not significantly different from the mean % FP levels (p > 0.05). The validation in this study indicates that (99m)Tc can act as a suitable marker for HFAFP, delivered via pMDI-spacer.</p>","PeriodicalId":14878,"journal":{"name":"Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine","volume":"19 3","pages":"254-60"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/jam.2006.19.254","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/jam.2006.19.254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The purpose of the study was to label Flixotide (fluticasone propionate [FP] with HFA propellant), with technetium-99m and validate that (99m)Tc acts as a suitable marker for FP when delivered via pMDI-spacer. Sodium pertechnetate was mixed with 5 mL of butanone. (99m)Tc was extracted into butanone and transferred into an empty canister. The (99m)Tc lined canister was heated, and the butanone evaporated to dryness. A supercooled commercial Flixotide canister was decrimped, and the contents transferred to the (99m)Tc lined canister and recrimped. The particle size distribution of FP and (99m)Tc from 10 radiolabeled canisters was measured using an Anderson cascade impactor calibrated to 28.3 L/min, and compared to commercial FP. The drug (FP) content of each particle size fraction was measured using ultraviolet spectrophotometry and the (99m)Tc level in each fraction was measured using an ionization chamber. The percentage of particles in the fine particle fraction (<;4.7 microm) and the percentage of (99m)Tc from commercial and radiolabeled canisters were compared. The mean (SD) % FP in the fine particle fraction, before and after label was 43.2 (1.8) % and 43.9 (2.6) %, respectively. The mean (SD) % (99m)Tc in the fine particle fraction was 42.1 (5.1) %. The mean %FP exiting spacer at (<4.7 microm) before labeling was not significantly different from the mean % FP exiting spacer at (<4.7 microm) after labeling (p > 0.05). The mean % (99m)Tc attached to particles at (<4.7 microm) after radiolabeling was not significantly different from the mean % FP levels (p > 0.05). The validation in this study indicates that (99m)Tc can act as a suitable marker for HFAFP, delivered via pMDI-spacer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
pmdi -间隔剂递送99mTc-HFA-FP的体外验证。
本研究的目的是用锝-99m标记氟替卡松(用HFA推进剂标记丙酸氟替卡松[FP]),并验证(99m)Tc通过pmdi -间隔剂传递时作为FP的合适标记物。将高技术酸钠与5ml丁酮混合。(99m)Tc提取成丁酮,转移到空罐中。加热(99米)Tc内衬的罐子,丁酮蒸发至干燥。将一个过冷的商用氟xotide罐进行压缩,并将内容物转移到(99m)Tc内衬罐中并进行压缩。使用校准为28.3 L/min的安德森级联冲击器测量了10个放射性标记罐中FP和(99m)Tc的粒度分布,并与商用FP进行了比较。采用紫外分光光度法测定各粒径组分的药物(FP)含量,用电离室测定各粒径组分的(99m)Tc含量。细粒分数中颗粒的百分比(0.05)。Tc附着在粒子上的平均百分比(99m)为(0.05)。本研究的验证表明(99m)Tc可以作为HFAFP的合适标记物,通过pMDI-spacer传递。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Formoterol turbuhaler is as effective as salbutamol diskus in relieving adenosine-induced bronchoconstriction in children. An in vitro study to assess facial and ocular deposition from Respimat Soft Mist inhaler. Exhaled breath condensate pH is increased after moderate exercise. The analysis and prediction of functional robustness of inhaler devices. Comparison of the Diskus inhaler and the Handihaler regarding preference and ease of use.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1